#1 Clinical Trials Search in Europe

Eltrombopag

Eltrombopag, a thrombopoietin receptor agonist, is being extensively studied in clinical trials for its potential to treat various blood disorders. This article explores the use of eltrombopag in conditions such as immune thrombocytopenia (ITP), aplastic anemia, and in enhancing platelet engraftment following cord blood transplantation. We’ll delve into the ongoing research, potential benefits, and safety considerations of this promising drug.

Table of Contents

What is Eltrombopag?

Eltrombopag is a medication used to treat various blood disorders. It is known by several brand names, including Promacta, Revolade, and Versapenia[1]. Eltrombopag is taken orally as a tablet and works by stimulating the production of blood cells in the bone marrow[2].

How Does Eltrombopag Work?

Eltrombopag is a thrombopoietin receptor agonist. This means it mimics the action of a natural substance in the body called thrombopoietin, which stimulates the production of platelets. Platelets are small blood cells that help with blood clotting. Eltrombopag works by binding to and activating the thrombopoietin receptor on certain cells in the bone marrow. This activation promotes the growth and development of cells that produce platelets (called megakaryocytes) and other blood cells[2][3].

What Conditions Does Eltrombopag Treat?

Eltrombopag is used to treat several blood disorders, including:

  • Immune Thrombocytopenia (ITP): A condition where the immune system mistakenly attacks and destroys platelets, leading to a low platelet count[4].
  • Aplastic Anemia: A rare but serious condition where the bone marrow fails to produce enough blood cells[1][2].
  • Thrombocytopenia in patients with chronic hepatitis C: Low platelet count in patients with liver disease caused by hepatitis C virus[5].
  • MYH9-related disorders: A group of rare genetic conditions affecting platelets and other body systems[6].
  • Poor Graft Function after stem cell transplantation: A complication where the transplanted stem cells fail to produce enough blood cells[7].

Dosage and Administration

The dosage of Eltrombopag varies depending on the condition being treated, the patient’s age, weight, and response to treatment. It is typically taken once daily by mouth, on an empty stomach (1-2 hours before or after a meal). The dose may be adjusted over time based on the patient’s response and blood test results[8][9].

For example, in some studies:

  • Adults may start with 50-75 mg per day, which can be increased up to 150 mg per day if needed[8].
  • Children’s doses are often based on weight, starting at 25-50 mg per day for those weighing 20-40 kg, and adjusted as needed[9].

Efficacy of Eltrombopag

Clinical trials have shown promising results for Eltrombopag in treating various blood disorders:

  • In patients with severe aplastic anemia, about 40-45% of patients showed improvement in at least one blood cell type after treatment[2].
  • For immune thrombocytopenia, Eltrombopag has been effective in increasing platelet counts and reducing the need for platelet transfusions[4].
  • In patients who have undergone stem cell transplantation, Eltrombopag may help improve blood cell counts and reduce the need for transfusions[7].

Potential Side Effects

While Eltrombopag is generally well-tolerated, it can cause side effects. Common side effects may include:

  • Headache
  • Nausea
  • Diarrhea
  • Upper respiratory tract infections
  • Fatigue

More serious but rare side effects can include liver problems, blood clots, and changes in bone marrow cells. Your doctor will monitor you closely for these potential complications[5][3].

Ongoing Research

Researchers continue to study Eltrombopag to understand its full potential and long-term effects. Current areas of investigation include:

  • Its use in children with various blood disorders[8][9].
  • Combination therapy with other medications for improved outcomes[4].
  • Long-term safety and efficacy in different patient populations[5].
  • Its potential in enhancing platelet recovery after stem cell transplantation[10].

If you have a blood disorder and are considering Eltrombopag as a treatment option, discuss the potential benefits and risks with your healthcare provider. They can provide personalized advice based on your specific medical condition and needs.

Aspect Details
Drug Name Eltrombopag (also known as Promacta or Revolade)
Drug Class Thrombopoietin receptor agonist
Main Conditions Studied Immune thrombocytopenia (ITP), aplastic anemia, Fanconi anemia, enhancing platelet engraftment in cord blood transplantation
Administration Oral, daily dosing (doses vary based on condition, age, weight, and response)
Primary Outcomes Platelet count response, sustained response rates, time to response, hematologic improvements
Safety Considerations Monitoring for headaches, nausea, liver function abnormalities, thromboembolic events
Potential Benefits Increased platelet production, reduced bleeding risk, improved quality of life, potential for reduced transfusion dependence
Ongoing Research Combination therapies, use in pediatric populations, long-term safety and efficacy studies

FAQ

  • What is eltrombopag and how does it work? Eltrombopag is a thrombopoietin receptor agonist that stimulates the production of platelets. It works by binding to and activating the thrombopoietin receptor, which initiates signaling to increase the proliferation and maturation of megakaryocytes, the cells that produce platelets.
  • In which conditions is eltrombopag being studied? Eltrombopag is being studied in various blood disorders, including immune thrombocytopenia (ITP), aplastic anemia, Fanconi anemia, and to enhance platelet engraftment in patients undergoing cord blood transplantation.
  • How is eltrombopag administered in clinical trials? Eltrombopag is typically administered orally, with dosages varying based on the condition being treated, patient age, weight, and response to treatment. Doses can range from 25 mg to 300 mg daily, with adjustments made based on platelet count response.
  • What are the primary outcomes measured in eltrombopag clinical trials? The primary outcomes often include platelet count response, sustained response rates, time to response, and overall hematologic improvements. Safety and tolerability are also key considerations in these trials.
  • Are there any potential side effects or safety concerns with eltrombopag? While eltrombopag is generally well-tolerated, potential side effects can include headaches, nausea, and liver function abnormalities. Some trials also monitor for more serious events such as thromboembolic complications. Safety is closely monitored in all clinical trials.

Ongoing Clinical Trials on Eltrombopag

  • Study on Eltrombopag for Treating Low and Intermediate Risk Myelodysplastic Syndromes in Patients with Thrombocytopenia

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study on the Effectiveness of Eltrombopag in Combination with Other Drugs for Patients with Immune Thrombocytopenia

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia

  • A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +5

Glossary

  • Thrombopoietin receptor agonist: A type of drug that stimulates the production of platelets by activating the thrombopoietin receptor on megakaryocytes.
  • Immune thrombocytopenia (ITP): A blood disorder characterized by a low platelet count due to the immune system mistakenly attacking and destroying platelets.
  • Aplastic anemia: A rare but serious blood disorder in which the body stops producing enough new blood cells, leading to fatigue and a higher risk of infections and uncontrolled bleeding.
  • Fanconi anemia: A rare, inherited blood disorder that leads to bone marrow failure and can affect all blood cell types.
  • Cord blood transplantation: A procedure where stem cells from umbilical cord blood are used to replace damaged or diseased bone marrow.
  • Platelet engraftment: The process by which transplanted stem cells begin producing new platelets in the recipient's body.
  • Megakaryocytes: Large bone marrow cells responsible for producing platelets.
  • Thrombocytopenia: A condition characterized by abnormally low levels of platelets in the blood, which can lead to easy bruising and bleeding.
  • Hematologic response: An improvement in blood cell counts or function as a result of treatment.
  • Thromboembolic events: Complications involving blood clots that can occur as a potential side effect of treatments that increase platelet counts.

References

  1. https://clinicaltrials.gov/study/NCT06493981
  2. https://clinicaltrials.gov/study/NCT00922883
  3. https://clinicaltrials.gov/study/NCT01891994
  4. https://clinicaltrials.gov/study/NCT04518475
  5. https://clinicaltrials.gov/study/NCT00643929
  6. https://clinicaltrials.gov/study/NCT01133860
  7. https://clinicaltrials.gov/study/NCT03437603
  8. https://clinicaltrials.gov/study/NCT06045052
  9. https://clinicaltrials.gov/study/NCT01940562
  10. https://clinicaltrials.gov/study/NCT01757145